Mosaic ImmunoEngineering Inc.
Close on Oct 19, 2026
- Market cap
- $2.41M
- P/E (TTM)
- –
- Dividend yield
- –
About Mosaic ImmunoEngineering
Biological Products, (No Diagnostic Substances), SIC 2836
Mosaic ImmunoEngineering, Inc. is a development-stage biotechnology company focused on advancing and commercializing immunotherapies for the treatment of cancer. The company works to identify, acquire, or license new product candidates and platforms to construct a product pipeline centered around cancer immunotherapy treatments. It has previously engaged in advisory and related services for external study projects. The company does not currently maintain an active development pipeline and seeks to serve medical patients through potential future therapeutic solutions.
The company operates in the biotechnology sector without commercial products or active development facilities detailed in its filings. Its corporate activities are based in the United States, and its executive offices are located in Huntington Beach, California.
Summary of the business section of Mosaic ImmunoEngineering's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Mosaic ImmunoEngineering Inc.
- Founded
- 2020
- Headquarters
- Huntington Beach, CA
- Address
- 9114 Adams Ave., #202 92646
- Phone
- (657) 208-0890
- Website
- mosaicie.com
- Employees
- 2, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Rose, Snyder& Jacobs LLP, Encino, California
Stock & identifiers
- Ticker
- CPMV
- Exchange
- OTC
- IPO date
- Jan 2, 2013
- Shares outstanding
- 7M, Aug 14, 2026
- Public float
- $856.00K, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-500 reverse, Dec 2, 2020
- SEC CIK
- 836564
- CUSIP
- 61945M101
- ISIN
- US61945M1018
- LEI
- 529900U2Q1RYN2NXNS45
- EIN
- 84-1070278
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Mosaic ImmunoEngineering's leadership is listed in its proxy statement (Form DEF 14A).
Employees
Headcount reported in annual reports
“At December 31, 2025, we have two full-time employees and five part-time employees, most of which, have been generally inactive due to insufficient capital.”
Corporate history
Events identified from SEC filings